Genotyping of different varicella vaccine strains

Journal of Clinical Virology

Volumn 37, Issue 2, 2006, Pages 109-117

  Sauerbrei, A ^a   Zell, R ^a   Harder, M ^a   Wutzler, P ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Single nucleotide polymorphism; Varicella vaccines; Varilrix ; Varivax

Indexed keywords

CHICKENPOX VACCINE; DNA FRAGMENT; NUCLEOTIDE; VARICELLA ZOSTER VACCINE;

ARTICLE; COMPARATIVE STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG SYNTHESIS; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VARICELLA ZOSTER VIRUS; VIRUS ATTENUATION; VIRUS ISOLATION; VIRUS STRAIN; WILD TYPE;

AMINO ACID SUBSTITUTION; CHICKENPOX VACCINE; GENOTYPE; HERPESVIRUS 3, HUMAN; HUMANS; OPEN READING FRAMES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33748967053     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.07.002     Document Type: Article

References (40)

1. Argaw T., Cohen J.I., Klutch M., Lekstrom K., Yoshikawa T., Asano Y., et al. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella zoster isolates. J Infect Dis 181 (2000) 1153-1157
2. Arvin A.A. Varilrix GlaxoSmithKline. Curr Opin Invest Drugs 3 (2002) 996-999
3. Barrett-Muir W., Nichols R., and Breuer J. Phylogenetic analysis of varicella-zoster virus: evidence variation of varicella-zoster virus-evidence of intercontinental spread of genotypes and recombination. J Virol 76 (2002) 1971-1979
4. Barrett-Muir W., Scott F.T., Aaby P., John J., Matondo P., Chaudhry Q.L., et al. Genetic variation of varicella-zoster virus: evidence for geographical separation of strains. J Med Virol 70 (2003) S42-S47
5. Carr M.J., McCormack G.P., and Crowley B. Genetic variation in clinical varicella-zoster virus isolates collected in Ireland between 2002 and. J Med Virol 73 (2004) 131-136
6. Cohr R.J., Gilden D.H., Gomi Y., Yamanishi K., and Cohen J. Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of varicella-zoster virus. J Virol 80 (2006) 2076-2082
7. D'Hondt E., Berge E., Colinet G., Duchene M., and Peetermans J. Production and quality control of the Oka-strain live varicella vaccine. Postgrad Med J 61 Suppl. 4 (1985) 53-56
8. Faga B., Maury W., Bruckner D.A., and Grose C. Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome. Virology 280 (2001) 1-6
9. Gershon A.A. Live attenuated varicella vaccine. Int J Infect Dis 1 (1997) 130-134
10. Gershon A.A. The current status of live attenuated varicella vaccine. Arch Virol 17 Suppl. (2001) 1-6
11. Gomi Y., Imagawa T., Takahashi M., and Yamanishi K. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 61 (2000) 497-503
12. Gomi Y., Imagawa T., Takahashi M., and Yamanishi K. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses. Arch Virol 17 Suppl (2001) 49-56
13. Gomi Y., Sunamachi H., Mori Y., Nagaike K., Takahashi M., and Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 76 (2002) 11447-11459
14. LaRussa P., Lungu O., Hardy I., Gershon A., Steinberg S.P., and Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 66 (1992) 1016-1020
15. Lau Y.L., Vessey S.J., Chan I.S., Lee T.L., Huang L.M., Lee C.Y., et al. A comparison of safety, tolerability, and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 20 (2002) 2942-2949
16. Levin M.J., Dahl K.M., Weinberg A., Giller R., Patel A., and Krause P.R. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 188 (2003) 954-959
17. Liang G.L., Heidelberg K.A., Jacobson R.M., and McEvoy M.T. Herpes zoster after varicella vaccination. J Am Acad Dermatol 38 (1998) 761-763
18. Loparev V.N., Gonzalez A., Deleon-Carnes M., Tipples G., Fickenscher H., Torfason E.G., et al. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol 78 (2004) 8349-8358
19. Loparev V.N., Argaw T., Krause P.R., Takayama M., and Schmid D.S. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 38 (2000) 3156-3160
20. Pinot de Moira A., Nardone A., and the ESEN2 group. Varicella-zoster virus vaccination policies and surveillance strategies in Europe. Eur Surveill 10 (2005) 43-45
21. Quinlivan M., Hawrami K., Barrett-Muir W., Aaby P., Arvin A., Chow V.T., et al. The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. J Infect Dis 186 (2002) 888-894
22. Quinlivan M.L., Gershon A.A., Steinberg S.P., and Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 190 (2004) 793-796
23. Rentier B., and Gershon A.A. The Oka varicella vaccines are more equal than different. Vaccine 22 (2004) 3225-3226
24. Saiki R.K., Bugawan T.L., Horn G.T., Mullis K.B., and Erlich H.A. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 324 (1986) 163-166
25. Sauerbrei A., Eichhorn U., Gawellek S., Egerer R., Schacke M., and Wutzler P. Characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain. J Med Virol 71 (2003) 313-319
26. Sauerbrei A., Eichhorn U., Schacke M., and Wutzler P. Laboratory diagnosis of herpes zoster. J Clin Virol 14 (1999) 31-36
27. Sauerbrei A., Rubtcova E., Wutzler P., Schmid D.S., and Loparev V. Genetic profile of Oka varicella vaccine virus variant isolated from an infant with zoster. J Clin Microbiol 42 (2004) 5604-5608
28. Sauerbrei A., Uebe B., and Wutzler P. Molecular diagnosis of zoster postvaricella vaccination. J Clin Virol 27 (2003) 190-199
29. Sears L.E., Moran L.S., Kissinger C., Creasey T., Perry-O'Keefe H., Roskey M., et al. Circumvent thermal cycle sequencing and alternative manual and automated DNA sequencing protocols using the highly thermostable VentR (exo-) DNA polymerase. Biotechniques 13 (1992) 626-633
30. Sharrar R.G., LaRussa P., Galea S.A., Steinberg S.P., Sweet A.R., Keatley R.M., et al. The postmarketing safety profile of varicella vaccine. Vaccine 19 (2001) 916-923
31. Slatko B.E. Thermal cycle dideoxy DNA sequencing. Mol Biotechnol 6 (1996) 311-322
32. Ständige Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2004. Epidemiol Bull 2004;30:235-50.
33. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T., and Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet ii (1974) 1288-1290
34. Takayama M., and Takayama N. New method of differentiating wild-type varicella-zoster virus (VZV) strains from Oka varicella vaccine strain by VZV ORF-based PCR and restriction fragment length polymorphism analysis. J Clin Virol 29 (2004) 113-119
35. Uebe B., Sauerbrei A., Burdach S., and Horneff G. Herpes zoster by reactivated vaccine varicella-zoster virus in a healthy child. Eur J Pediatr 161 (2002) 442-444
36. Vassilev V. Stable and consistent genetic profile of Oka varicella vaccine virus is not linked with appearance of infrequent breakthrough cases postvaccination. J Clin Microbiol 43 (2005) 5415-5417
37. Vázquez M., and Shapiro E.D. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 352 (2005) 439-440
38. Wagenaar T.R., Grose C., Loparev V.N., Schmid D.S., and Breuer J. Genomic analysis of varicella-zoster virus: primers for individual open reading frames. J Clin Virol 28 (2003) 104-110
39. Watson B. Varicella: a vaccine preventable disease?. J Infect 44 (2002) 220-225
40. Zerboni L., Hincliffe S., Sommer M.H., Ito H., Besser J., Stamatis S., et al. Analysis of varicella-zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 332 (2005) 337-346